Posted in | News | Nanomedicine | Nanobusiness

Oxford Nanopore Announces Participation in READNA Project

Oxford Nanopore Technologies ("Oxford Nanopore") today announced its participation in the Revolutionary Approaches and Devices for Nucleic Acid analysis project (READNA). The newly-launched READNA consortium includes researchers from 16 academic and industrial institutions and will receive €12m in funding over four years, under the European Union's Seventh Framework Programme (FP7).

As part of the consortium, Oxford Nanopore will receive €730,000 in grant funding to support the development of its nanopore technology into an early exonuclease/nanopore DNA sequencing system. The Company will also work on projects to integrate protein nanopores and solid-state materials for the further progression of nanopore sequencing, the development of a new technique that uses nanopores for genome-wide methylation studies and the development of droplet-based bilayer arrays for rapid, multiplexed genotyping.

Oxford Nanopore will collaborate closely with researchers from the University of Oxford, including Professor Hagan Bayley's Chemical Biology group, the Biological Physics group and the Wellcome Trust Centre for Human Genetics. The University will receive €2m to support READNA projects.

"We are proud to be part of the READNA project, which includes representatives from Europe's leading research institutions and developers of genomic technologies," said Dr Gordon Sanghera, CEO of Oxford Nanopore. "The consortium aims to revolutionise nucleic acid analysis. Our role as the developer of a new generation of sequencing technology, based on nanopores, is critical to the project. With support also being given to our academic collaborators, we believe we are in the best position to deliver a meaningful improvement in sequencing technology with our label-free, single-molecule nanopore system."

The READNA consortium aims to revolutionise the analysis of nucleic acids by the improvement of existing methods and the development of new technologies.

Specific goals of the project include:

  • Development of a new generation of rapid and cost effective sequencing methodologies
  • Single molecule detection of DNA molecules in nanosystems using nanopores and nanochannels
  • Improvement of elements of existing sequencing systems
  • Methods for the detection and the enrichment of rare mutations from peripheral patient samples
  • Combining RNA and DNA analysis in a single analytical device
  • Development of methods for genome-wide analysis of DNA methylation at a high resolution
  • Development of cost-effective high resolution HLA typing
  • Development of assays for effective high-resolution genotyping of copy number variations
  • Overall, the project aims to progress towards a target of sequencing a complete human genome for €1000; the promotion of new sequencing technologies is central to this goal.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Nanopore Technologies Ltd. (2019, February 15). Oxford Nanopore Announces Participation in READNA Project. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=9015.

  • MLA

    Oxford Nanopore Technologies Ltd. "Oxford Nanopore Announces Participation in READNA Project". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=9015>.

  • Chicago

    Oxford Nanopore Technologies Ltd. "Oxford Nanopore Announces Participation in READNA Project". AZoNano. https://www.azonano.com/news.aspx?newsID=9015. (accessed November 21, 2024).

  • Harvard

    Oxford Nanopore Technologies Ltd. 2019. Oxford Nanopore Announces Participation in READNA Project. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=9015.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.